Filter Results
:
(7)
Show Results For
- All HBS Web (7)
- Faculty Publications (1)
Show Results For
- All HBS Web (7)
- Faculty Publications (1)
Page 1 of
7
Results
- 2021
- Working Paper
Development of CAR-T Therapies: Case Histories of Significant Medical Advances
By: Amar Bhidé and Srikant M. Datar
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works; 2) the foundational advances and discoveries; 3)...
View Details
Keywords:
Immunotherapy;
Health Care and Treatment;
Innovation and Invention;
Research and Development;
Governing Rules, Regulations, and Reforms
Bhidé, Amar, and Srikant M. Datar. "Development of CAR-T Therapies: Case Histories of Significant Medical Advances." Harvard Business School Working Paper, No. 21-035, August 2020. (Revised May 2021.)
- 28 Nov 2016
- News
One Obstacle to Curing Cancer: Patient Data Isn’t Shared
- Web
Faculty & Advisors - MBA
a total value greater than $5 billion and actively partnered with the science team to develop a cancer immunotherapy strategy which ultimately guided Celgene into the rapidly developing field of immuno-oncology (IO). Kareem started his...
View Details
- 22 Feb 2024
- News
Combat-Tested Cancer Coaching
think I'll just rest on my laurels and see what happens now. I was equally as tenacious about finding the next immunotherapy drug that might come out. And so I think that balance was out of whack. I was so focused on that urgency. On the...
View Details
- Web
Kraft Accelerator
in Precision Medicine in Immunotherapy (video) Close DOWNLOAD ALL TOOLS Discover how others in the community are provoking positive change Learn from Leaders Before you download the tool Please complete the form: Your First Name* Your...
View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
therapies has become a reality, as have immunotherapies that induce or suppress a body’s immune response to treat disease. Yet, this relatively swift progress has not been fast enough for millions of other patients who still lack...
View Details